

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084538 A1

(51) International Patent Classification⁷: **A61K 31/44**
(21) International Application Number: **PCT/US03/10316**
(22) International Filing Date: **4 April 2003 (04.04.2003)**
(25) Filing Language: **English**
(26) Publication Language: **English**
(30) Priority Data:
60/370,106 **4 April 2002 (04.04.2002)** **US**
(71) Applicant: **MEDICIS PHARMACEUTICAL CORPORATION [US/US]; 8125 North Hayden Road, Scottsdale, AZ 85258 (US).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventor: **GANS, Eugene, H.; 514 Harvest Commons, Westport, CT 06880 (US).**

Published:

— with international search report

(74) Agents: **McNICHOL, William, J., Jr. et al.; Reed Smith LLP, 2500 One Liberty Place, 1650 Market Street, Philadelphia, PA 19103 (US).**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS FOR TREATING ROSACEA WITH PYRIDONES**

(57) Abstract: The present invention is a method of treating rosacea and a method of preventing recurrences of rosacea manifestations by applying a composition comprising one or more 1-hydroxy-2-pyridones in a dermatologically acceptable carrier.

WO 03/084538 A1

METHODS FOR TREATING ROSACEA WITH PYRIDONES

Field of the Invention

5 The present invention relates to composition and methods for the treatment of acne rosacea manifested in the skin and the prevention of recurrences of the manifestations.

Background of the Invention

10 Acne rosacea is a skin disorder of unknown etiology. A patient with acne rosacea may have varied manifestations of the disorder, including but not limited to erythema, pustules, papules, lesions, inflammation, infection and enlarged nasal area. Acne rosacea, also referred to as rosacea, is a chronic disorder which may be treated and manifestations may be prevented or controlled, but the underlying disorder has not been clinically eliminated.

15 Acne rosacea is distinct from and not related to acne vulgaris, which is often referred to as "acne". Acne vulgaris "is a disorder of the pilosebaceous follicle: common features include increased sebum production, follicular keratinization, colonization by *Propionibacterium acnes*, and localized inflammation." Acne rosacea is a separate distinct dermatological disorder, which is "a chronic inflammatory skin disorder characterized by enhanced
20 epidermal proliferation leading to erythema, scaling, and thickening of the skin." Martindale, The Complete Drug Reference, 32d ed. (1999) 1072, 1076. See Fitzpatrick, Dermatology in General Medicine, 5th edition, CD-ROM (1999). The present invention is directed to methods of treating and preventing recurrences of acne rosacea manifestations.

25 Rosacea may be diagnosed due to the presence of one or more of its manifestations. Patients with rosacea may have different triggering factors for the manifestations. These triggering factors may include, for example, any one of the following: genetic disposition, gastrointestinal disturbances (including dyspepsia with gastric hypochlorhydria and infestation with
30 microaerophilic gram-negative bacteria *Helicobacter pylori*), hypertension, *Demodex folliculorum* mites, psychogenic factors, spicy foods, blushing, flushing, ultraviolet radiation, wind exposure, and stress. Often patients with

rosacea are particularly susceptible to blushing and flushing, and signs of this may be an indicator of the probability of rosacea suffering later in life. Rosacea usually first manifests in the patient in their 20s, 30s or later in life.

5 There are several phases of the disorder, set forth in order of increasing severity. Early signs are episodes of blushing which become persistent dark-red erythema, particularly on the nose and cheeks. In the worst cases, disfigurement (e.g. hypertrophy, particularly rhinophyma of the nose) may later develop. See, Fitzpatrick, *Dermatology in General Medicine*, 5th ed., CD-ROM, 1999, Chapter 74. Granulomatous changes can emerge in later
10 stages, sometimes receiving special designations such as lupoid rosacea. Rhinophyma and other phys are the ultimate tissue reaction, especially in men.

15 In stage I, erythema persists for hours and days, often called *erythema congestivum*. Telangiectases become more extensive by forming sprays on the nose, nasolabial folds, cheeks, and glabella. Often the patients have sensitive skin that stings and burns after any applications to the skin.

20 Stage II includes the eruption of inflammatory papules and pustules, and often these persist for weeks. Small pustules often appear at the apex of some papules. The lesions are follicular in origin (e.g. the vellus and sebaceous follicles). Scarring may occur as lesions heal and facial pores may become more prominent. Stigmata of photodamaged skin may be superimposed and papulopustular attacks become more and more frequent. The lesions may extend over the face and scalp.

25 Some of the worst manifestations of the disease, large inflammatory nodules, furunculoid infiltrations and tissue hyperplasia, develop in a small number of Stage III patients. These manifestations occur on the cheeks, nose, chin, forehead and ears. Facial contours become coarse, thickened and irregular. Ultimately the skin becomes inflamed, thickened edematous skin with large pores (*peau d'orange*) is observed. The ultimate deformities are the phymas,
30 e.g. rhinophyma.

Rosacea is difficult to treat and cures are often not possible. Treatments for rosacea and its manifestations have typically centered upon the use of sulfur

based compositions (such as lotions with 2-5% sulfur). These prior art compositions have the disadvantage of having a malodor which is caused by the presence of sulfur and its derivatives. Patient compliance with the prescribed treatment of applying these sulfur compositions to the skin, especially the face, once or twice daily, is often very poor.

Further, some patients may be unable to use sulfur based compositions due to an allergic sensitivity to sulfur and its derivatives. Some patients may then have uncontrolled manifestations of rosacea, and progress unchecked to more advanced stages of the disorder, which can ultimately result in a disfigured appearance of the face.

Rosacea patients have skin areas that are usually vulnerable to chemical and physical insults. Only mild soaps or properly diluted detergents are advised. Sunlight protection is required, but it may be difficult to find a sunscreen that is tolerated without burning or irritation.

Antibiotics (such as topical clindamycin and erythromycin) are sometimes used as effective treatments. Tetracycline may be effective in oral form, especially minocycline and doxycycline. Azoles, e.g. metronidazole and imidazoles, have been used as treatments, particularly for moderate to severe rosacea.

In some instances, patients have been successfully treated with retinoids (such as 0.025% tretinoin cream). There is preliminary evidence that 0.2% isotretinoin in a bland cream, which is less irritating than tretinoin, suppresses inflammatory lesions in stages II and III. Other patients have found relief with oral retinoids (e.g. isotretinoin capsules, such as Accutane®).

Summary of the Invention

The present invention comprises a method of treating (including but not limited to a partial relief or reduction) and/or preventing recurrences of rosacea manifestations. Rosacea manifestations include but are not limited to vivid red erythema, papulopustules (referred to as pustules), papules and telangiectases, preceded by episodes of flushing. In severe cases, papules are numerous enough to be confluent, and phymas may evolve. The treatment

method comprises topically applying 1-hydroxy-2-pyridones to the skin effected by rosacea. The method of prevention of recurrences of rosacea manifestations comprises topically applying 1-hydroxy-2-pyridones to skin that either currently is or was effected by rosacea.

5 1-hydroxy-2-pyridones applied topically for rosacea treatment or recurrence prevention may also be combined with the topical application of benzoyl peroxide, sulfur, sodium sulfacetamide, antibiotics (such as, without limitation, tetracycline, doxycycline, clindamycin, erythromycin, minocycline), retinoid compositions (such as, without limitation, natural
10 retinoids, synthetic retinoids, retinoic acid, retinal, retinol, adapalene, tazarotene, isotretinoin, their derivatives, isomers and analogs), azoles (such as, without limitation imidazoles, metronidazole), anti-inflammatory agents which are also antimicrobial agents ("anti-inflammatory and antimicrobial agents"), immunosuppressants (immunosuppressants in the present invention
15 are suitable for topical use, e.g. Pimecrolimus 1 %), other agents which treat inflammation, rosacea lesions or manifestations, and/or possible infection associated with rosacea, or combinations thereof. These ingredients may be applied topically in the same composition as the pyridone, or in separate compositions, which are also topically applied.

20 The present invention also comprises applying 1-hydroxy-2-pyridones topically as one part of a joint treatment or prevention program for rosacea. The other part of the rosacea treatment is oral administration of one or more of antibiotics, retinoid compositions, anti-inflammatory and antimicrobial agents, or immunosuppressants, which are bioavailable in oral form.

25 Brief Description of the Drawings

Figure 1 depicts the results noted by the investigator on the decrease of erythema in lesion areas in the study of Example 1.

Figure 2 depicts the results noted by the investigator on the decrease of erythema in non-lesion areas in study of Example 1.

30 Figure 3 depicts the results noted by the investigator on the reduction of papules in the study of Example 1.

Figure 4 depicts the results noted by the investigator on the reduction of pustules in the study of Example 1.

Figure 5 depicts the results noted by the investigator on the decrease of overall rosacea severity in the study of Example 1.

5 Figure 6 depicts the results of the subject's self-assessment on their overall improvement in the study of Example 1.

Figure 7 depicts the results of the subject's self-assessment on the embodiment of the present invention's efficacy.

10 Figure 8 depicts the results of the subject's self-assessment on the decrease of overall rosacea severity in the study of Example 1.

Detailed Description of the Preferred Embodiments

The present invention is a composition comprising one or more 1-hydroxy-2-pyridones in a dermatologically acceptable carrier. The 1-hydroxy-2-pyridones, include, but are not limited to 1-hydroxy-4,6-dimethyl-2-pyridone, 15 1-hydroxy-3,4,6-trimethyl-2-pyridone, 1-hydroxy-4-methyl-6-ethyl-2-pyridone, 1-hydroxy-4,6-dimethyl-5-ethyl-2-pyridone, 1-hydroxy-4-ethyl-5,6-dimethyl-2-pyridone, 1-hydroxy-3-ethyl-4-methyl-6-isobutyl-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexylmethyl-2-pyridone, 1-hydroxy-4-methyl-6-(β -cyclohexylethyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-cyclopentyl-2-pyridone, 1-hydroxy-4-methyl-6-chloromethyl-2-pyridone, 1-hydroxy-4-methyl-6-(β -chloroethyl)-2-pyridone, 1-hydroxy-4-methyl-6-bromoethyl-2-pyridone, 1-hydroxy-4-methyl-6-isopropyl-2-pyridone, 1-hydroxy-3,6-dibutyl-4-methyl-2-pyridone, 1-hydroxy-4-methyl-6-heptyl-2-pyridone, 1-hydroxy-4-methyl-6-undecyl-2-pyridone, 1-hydroxy-3,4-dimethyl-6-benzyl-2-pyridone, 1-hydroxy-4-methyl-6-(4-chlorobenzyl)-2-pyridone, 1-hydroxy-4,5-trimethylene-6-methyl-2-pyridone, 1-hydroxy-4-methyl-6-(α -furyl)-2-pyridone, 1-hydroxy-3,4-dimethyl-6-(4-fluorobenzyl)-2-pyridone, preferably ciclopirox (6-(4-(4-chlorophenoxy)-phenoxy)methyl)-1-hydroxy-4-methyl-2(1H)) pyridone, 25 ciclopirox olamine, or salts of ciclopirox including but not limited to amine 30

salts, alkaline metal salts, alkanolamine salts, other derivatives of ciclopirox or other forms of ciclopirox.

5 The carrier for the present invention is a composition that contacts the skin long enough to effect the treatment or prevention and preferably absorbs into the affected cutaneous tissues. Different embodiments of carriers include, but are not limited to lotions, ointments, gels, creams, masks, cleansers, solutions, suspensions, emulsions, sprays, or other dermatologically acceptable forms.

10 The 1-hydroxy-2-pyridones may be present at about 0.10 to about 5.0% of the total compositions, preferably about 0.10 to about 1.5%, more preferably about 0.10 to about 1.0%. All percentages in this specification, unless otherwise noted, are given as weight percents.

15 Further, another embodiment of the present invention comprises a method of treating rosacea, including but not limited to rosacea lesions. Rosacea lesions are defined to include but are not limited to papules, pustules, and erythema. The method of treatment comprises applying a composition, comprising one or more 1-hydroxy-2-pyridones (preferably ciclopirox, ciclopirox olamine, or salts of ciclopirox including but not limited to amine salts, alkaline metal salts, alkanolamine salts, other derivatives of ciclopirox or other forms of ciclopirox) in a dermatologically acceptable carrier, to skin effected by
20 rosacea and/or its manifestations.

25 Additionally, another embodiment of the present invention comprises a method of prevention of rosacea manifestation recurrences. A composition, comprising one or more 1-hydroxy-2-pyridones in a dermatologically acceptable carrier, is applied to skin, which in the past showed manifestations of rosacea but does not display its manifestations presently.

30 A combination method may also be used for treatment of rosacea. A topical composition comprises one or more 1-hydroxy-2-pyridones and one or more of the following: benzoyl peroxide, sulfur, sodium sulfacetamide, antibiotics (such as, without limitation, tetracycline, doxycycline, clindamycin, erythromycin, and minocycline), retinoid compositions (such as, without limitation, natural retinoids, synthetic retinoids, retinoic acid, retinal, retinol, adapalene, tazarotene, isotretinoin, their derivatives, isomers and analogs), azoles

(such as, without limitation, imidazoles, and metronidazole), anti-inflammatory and antimicrobial agents, immunosuppressants, or other agents which treat inflammation, rosacea lesions or manifestations, and/or possible infection associated with rosacea, all in a dermatologically acceptable carrier.

5 The topical combination method may also be executed in this manner. A topical composition comprising one or more 1-hydroxy-2-pyridones in a dermatologically acceptable carrier is applied to the skin effected by rosacea. A separate composition comprising one or more of: benzoyl peroxide, sulfur, sodium sulfacetamide, antibiotics (such as, without limitation, tetracycline,
10 doxycycline, clindamycin, erythromycin and minocycline), retinoid compositions (such as, without limitation, natural retinoids, synthetic retinoids, retinoic acid, retinal, retinol, adapalene, tazarotene, isotretinoin, their derivatives, isomers and analogs), azoles (such as, without limitation, imidazoles and metronidazole), anti-inflammatory and antimicrobial agents,
15 immunosuppressants, or other agents which treat inflammation, rosacea lesions or manifestations, and/or possible infection associated with rosacea in a dermatologically acceptable carrier may be applied to the same skin simultaneously, or in sequence with the topical application of the 1-hydroxy-2-pyridone composition.

20 A different embodiment of the treatment method combines the use of topical and oral compositions. A topical composition comprising one or more 1-hydroxy-2-pyridones in a dermatologically acceptable carrier is applied to the skin effected by rosacea. An oral composition comprising one or more of the following: antibiotics or retinoid compositions, in the oral bioavailable form,
25 is administered to the rosacea sufferer. Oral composition may be in the following forms, without limitation, capsules, tablets, caplets, syrups, or solutions. The topical and oral compositions may be administered simultaneously, or in sequence.

30 Each of the foregoing embodiments of the present invention may also be used for prevention of rosacea manifestation recurrences. In some embodiments, treatment of rosacea may occur simultaneously with prevention of rosacea manifestations recurrences.

Example 1

A twelve week study was conducted to evaluate the present invention in comparison with a prior art rosacea (and its manifestations) treatment and prevention composition, Metrogel by Galderma Corp.

5 Twelve subjects were evaluated at the baseline and after 4, 8, and 12 weeks. Each subject applied Metrogel and an embodiment of the present invention (set forth on Table 1) to separate areas of the face which had manifestations of rosacea. Rosacea manifestations included but were not limited to irritation, itching, burning, stinging, erythema and pustules.

TABLE I

INGREDIENT	Weight Percent
Ciclopirox Olamine	1.000
Benzyl Alcohol NF	1.000
Octyl Dodecanol NF	2.013
Mineral Oil	2.013
Stearyl Alcohol NF	2.013
Cetyl Alcohol NF	2.013
Myristyl Alcohol NF	1.050
Polysorbate 60 NF	1.225
Sorbitan Monostearate NF	0.525
Cocamide DEA	4.000
Lactic Acid USP	0.585
Purified Water USP	82.563

Both an investigator and each subject evaluated the treatment of the rosacea and its manifestations and prevention of additional manifestations. Figures 1-8 depict the results of this study, and in each of the figures, the solid line corresponds to the results from Metrogel, and the broken line corresponds to the results from the present embodiment of the invention. The vertical axis depicts the severity, zero denoting the least severe, between 2 and 3 denoting mild, between 4 and 5 denoting mild-moderate, and between 6 and 7 denoting moderate, while above 7 denotes severe. Figure 3 has a vertical axis which denotes the percent reduction in papules. The horizontal axis depicts the number of weeks since the start of the study.

As shown in Figures 1-5, the investigator assessed the embodiment of the present invention (comprising 1.00% ciclopirox olamine, which is equivalent to 0.77% ciclopirox olamine) as effective as Metrogel at 4 weeks and 12 weeks in the reduction of papules, and better than Metrogel at 8 weeks. The present embodiment was better at reducing pustules than Metrogel, and both the present embodiment and Metrogel were effective in reducing erythema in both lesion and non-lesion areas. The embodiment and Metrogel both appeared to prevent new manifestations of rosacea. Metrogel and the embodiment were both found to be very effective in the reduction of rosacea severity.

The self-assessments yielded the following results in Figures 6-8. Metrogel and the present embodiment were found to be comparable and very effective in the reduction of rosacea severity. The subjects reported that at 8 weeks Metrogel and the present embodiment were very comparable in their treatment of the manifestations, and that the present embodiment is as active as Metrogel in treatment and prevention of rosacea and its manifestations after 8 and 12 weeks.

Example 2

A formula for another embodiment is set forth in Table 2.

Table 2

INGREDIENT	Weight Percent
------------	----------------

Ciclopirox Olamine	1.000
Benzyl Alcohol NF	1.000
Octyl Dodecanol NF	2.013
Mineral Oil	2.013
Stearyl Alcohol NF	2.043
Cetyl Alcohol NF	2.043
Myristyl Alcohol NF	1.066
Polysorbate 60 NF	1.225
Sorbitan Monostearate NF	0.525
Cocamide DEA	4.000
Lactic Acid USP	0.585
Purified Water USP	82.487

5 It may be desirable to alter the viscosity of the present invention. A preferred manner of increasing viscosity is increasing the alcohol amounts (especially the stearyl, cetyl and myristyl alcohol) and decreasing the water amount (and vice versa for decreasing the viscosity). Stearyl alcohol may be present preferably at about 1.5 to about 3%. Cetyl alcohol may be present preferably at about 1.5 to about 3%. Myristyl alcohol may be present preferably at about 0.8 to about 1.5%.

10 It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are evident from a review of the following claims.

What is claimed is:

1. A method of treating rosacea comprising

Applying a composition to skin with one or more rosacea manifestations, wherein the composition comprises one or more 1-hydroxy-2-pyridones and a dermatologically acceptable carrier.

2. The method of claim 1 wherein the 1-hydroxy-2-pyridone comprises ciclopirox olamine.
3. The method of claim 2 wherein the 1-hydroxy-2-pyridone is present at about 0.10 to about 5.0% by weight of the total composition.
4. The method of claim 1 wherein the 1-hydroxy-2-pyridone is present at about 0.10 to about 1.0% by weight of the total composition.
5. The method of claim 1 wherein the 1-hydroxy-2-pyridone is present at about 0.5 to about 1.5% weight of the total composition.
6. The method of claim 1 wherein the carrier comprises one selected from the group consisting of lotion, ointment, gel, cream, mask, cleanser, solution, emulsion, spray, and suspension.
7. The method of claim 1 wherein the manifestations comprise erythema.
8. The method of claim 1 wherein the manifestations comprise pustules.
9. The method of claim 1 wherein the manifestations comprise papules.
10. The method of claim 1 wherein the 1-hydroxy-2-pyridone comprises one or more selected from the group consisting of ciclopirox, ciclopirox olamine, salts of ciclopirox, other derivatives of ciclopirox and other forms of ciclopirox which reduce ciclopirox on and/or within the skin.

11. The method of claim 1 wherein the composition further comprises an additional agent, said agent treats one or more selected from the group consisting of skin inflammation, rosacea lesions and infection associated with rosacea.

5 12. The method of claim 1 wherein the composition further comprises one or more selected from the group consisting of benzoyl peroxide, sulfur, sodium sulfacetamide, antibiotics, retinoid compositions, azoles, immunosuppressants, and anti-inflammatory and antimicrobial agents.

10 13. The method of claim 1 further administering orally a second composition, said second composition comprises one or more selected from the group consisting of antibiotics, anti-inflammatory and antimicrobial agents, immunosuppressants, and retinoid compositions.

14. A method of preventing rosacea manifestation recurrences comprising

15 applying a composition to skin which previously had one or more rosacea manifestations, wherein the composition comprises one or more 1-hydroxy-2-pyridones and a dermatologically acceptable carrier.

15. The method of claim 14 wherein the 1-hydroxy-2-pyridone comprises ciclopirox olamine.

20 16. The method of claim 14 wherein the 1-hydroxy-2-pyridone is present at about 0.10 to about 5.0% by weight of the total composition.

17. The method of claim 14 wherein the 1-hydroxy-2-pyridone is present at about 0.10 to about 1.0% by weight of the total composition.

18. The method of claim 14 wherein the 1-hydroxy-2-pyridone is present at about 0.5 to about 1.5% weight of the total composition.

25 19. The method of claim 14 wherein the carrier comprises one selected from the group consisting of lotion, ointment, gel, cream, mask, cleanser, solution, emulsion, spray, and suspension.

20. The method of claim 14 wherein the 1-hydroxy-2-pyridone comprises one or more selected from the group consisting of ciclopirox, ciclopirox olamine, salts of ciclopirox, other derivatives of ciclopirox and other forms of ciclopirox which reduce ciclopirox on and/or within the skin.


5 21. The method of claim 14 wherein the composition further comprises one or more additional agents, said agents treat one or more selected from the group consisting of skin inflammation, rosacea lesions and infection associated with rosacea.

10 22. The method of claim 14 wherein the composition further comprises one or more selected from the group consisting of benzoyl peroxide, sulfur, sodium sulfacetamide, antibiotics, retinoid compositions, azoles, immunosuppressants, and anti-inflammatory and antimicrobial agents.


15 23. The method of claim 14 further administering orally a second composition, said second composition comprises one or more selected from the group consisting of antibiotics, anti-inflammatory and antimicrobial agents, immunosuppressants, and retinoid compositions.

20

1/8

**ERYTHEMA ASSOCIATED
WITH LESIONS****FIG. 1**

2/8

**ERYTHEMA IN
NON-LESIONAL AREAS****FIG. 2**

3/8





FIG. 3

4/8

**FIG. 4**

5/8

INVESTIGATOR EVALUATION OF ROSACEA SEVERITY





FIG. 5

6/8

**SUBJECTS' SELF-ASSESSMENT OF
THEIR OVERALL IMPROVEMENT****FIG. 6**

7/8

SUBJECTS' SELF-ASSESSMENT OF PRODUCT EFFICACY




FIG. 7

8/8


SUBJECTS' EVALUATION
OF ROSACEA SEVERITY

FIG. 8

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/10316

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/44

US CL : 514/345

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/345

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- A	US 6,296,880 B1 (MURAD) 02 October 2001 (02.10.01), see the abstract, column 3, line 63, column 4, lines 22-56 and Example 14 at column 30 - column 31.	1-12 and 14-22 ----- 13 and 23

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search
30 May 2003 (30.05.2003)

Date of mailing of the international search report
19 JUN 2003

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703)305-3230

Authorized officer
Felicia D. Roberts for
Raymond J. Henley III
Telephone No. 703-308-1235

THIS PAGE BLANK (USPTO)